Prophylactic Intrawound Vancomycin Powder in Minimally Invasive Spine Stabilization May Cause an Acute Inflammatory

Yuki Hyodo1,2, Takeshi Arizono2, Akihiko Inokuchi2

  • 1Department of Orthopaedic Surgery, Kyushu University Hospital, Fukuoka, JPN.

Cureus
|October 13, 2022
PubMed

Insights

Intrawound vancomycin powder in minimally invasive spine surgery may cause an acute inflammatory response and low serum levels. Its use may be limited to patients at high risk for surgical site infections (SSIs).

Area of Science:

  • Orthopedics
  • Neurosurgery
  • Infectious Disease

Background:

  • Surgical site infections (SSIs) from methicillin-resistant Staphylococcus aureus are a concern in spinal instrumentation.
  • Prophylactic vancomycin powder use raises concerns about multidrug-resistant pathogens, allergies, and organ toxicity.
  • Minimally invasive spine stabilization (MISt) may reduce vancomycin risks due to shorter operation times and less blood loss.

Purpose of the Study:

  • To evaluate complications and local/serum levels of intrawound vancomycin powder versus IV cefazolin alone in MISt.
  • To compare white blood cell counts and C-reactive protein (CRP) levels postoperatively.
  • To assess serum and drain vancomycin levels and postoperative blood loss.

Main Methods:

  • Retrospective comparative study of 34 patients receiving intrawound vancomycin powder (1g) during minimally invasive posterior lumbar interbody fusion (MIS-PLIF).
  • Comparison with 133 control patients receiving IV cefazolin alone.
  • Measurement of white blood cell counts, CRP, serum vancomycin, and drain vancomycin levels on various postoperative days.

Main Results:

  • CRP levels were significantly higher on postoperative days 1 and 3 in the vancomycin group.
  • Mean drain vancomycin levels decreased from POD 1 (313 μg/mL) to POD 2 (155 μg/mL) and correlated negatively with drainage volume.
  • Mean serum vancomycin levels decreased from POD 1 (2.3 μg/mL) to POD 14 (1.7 μg/mL).

Conclusions:

  • Local vancomycin powder application induced an acute inflammatory response and prolonged low serum levels.
  • Less than 1g of intrawound vancomycin may be beneficial for patients at high risk of SSI.
  • Further research is needed to clarify the optimal use of intrawound vancomycin in MISt.